CONTACT
+91 80 2808 2808
info@biocon.com

Biocon Receives Approval for Antifungal Medication, Micafungin from US FDA

  • Posted by: BIOCON

Bengaluru, Karnataka, India, June 03, 2024

 

“Biocon Limited has received approval from the U.S. Food and Drug Administration (US FDA), for its vertically integrated, complex injectable drug product, Micafungin (50mg and 100mg vials), used as an antifungal medication to treat fungal or yeast infections.

The approval further strengthens Biocon’s portfolio of vertically integrated, complex drug products.”

Author: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>